You may have never heard of zombie cells, but your body naturally produces them. Their scientific name is senescent cells. These are cells that have stopped dividing but haven’t been cleared away by the body. In simple terms, they’re not dead—they’re damaged cells stuck in a weird limbo, no longer doing their original job but still messing with the surrounding tissue.
Senescent cells show up during tissue aging, chronic stress, and inflammatory processes. They can also lurk inside tumors, especially after treatments that force cancer cells to stop dividing. That might sound like a win at first. The problem? These cells keep pumping out chemical signals that drive inflammation, tweak nearby cells’ behavior, and sometimes even help tumors hang on.
Researchers searched a huge library of compounds for ones that could hit zombie cells
Scientists from the MRC Laboratory of Medical Sciences and Imperial College London tested 10,000 different chemical compounds. They weren’t hunting everyday drugs, but experimental molecules that could selectively kill senescent cells while sparing healthy ones.
They zeroed in on covalent electrophilic compounds. Sounds technical, but here’s the gist: these molecules latch onto specific proteins inside cells and tweak how they function. Hit the right target, and you disable a key survival trick that damaged cells rely on.
From the big screen, the team pinpointed compounds with senolytic activity—ones that kill senescent cells. They honed in on four promising chloroacetamide compounds. Three targeted the same defense system: a protein called GPX4, which shields cells from a iron-linked form of death. One standout, dubbed SCLA1 (or CLA01-P20 in the study), stole the show.
“Senescence was considered for a long time to be positive, because senescent cells don’t proliferate, which is the core feature of cancer. Normal chemotherapy induces senescence blocking the proliferation of cancer cells, so the tumour doesn’t get bigger. But with time you also see the negative side of the senescent cells, because they secrete a lot of factors that influence neighbouring cells and induce even more proliferation, metastasis, and recruitment of bad parts of the immune system that will provoke even more aggressiveness in the tumour. For this reason, we tried to find some drugs that were able to kill the senescent cells,” explains Mariantonietta D’Ambrosio, a postdoctoral researcher at the LMS.
Zombie cells hide behind a protective shield—without it, iron turns deadly
Senescent cells often pack extra iron and battle intense oxidative stress. Normally, that would drive them toward ferroptosis, a cell death where damage piles up in the fatty membranes until the cell bursts.
But zombie cells have a workaround. They crank out lots of GPX4 protein, which blocks ferroptosis like a shield. Picture running on a sprained ankle after popping heavy painkillers—the injury’s still there, the risk hasn’t vanished, but you’re masked enough to keep moving.
The researchers’ experimental senolytics punch holes in that shield. By gumming up GPX4, they leave senescent cells exposed. Suddenly, the iron stress they were barely dodging becomes a death sentence.
In mice, tumors shrank and the animals lived longer
The team tested the compounds in three different mouse cancer models. Each time, tumors shrank and survival improved. Promising stuff—but remember, this is preclinical work, not a ready-for-patients treatment.
The real hook? Pairing this with chemotherapy could be a game-changer. Chemo pushes some cancer cells into senescence, slowing tumor growth—but those zombie cells stick around, stirring trouble. These senolytics could swoop in as cleanup crew.
“In mouse models we saw that these drugs reduced tumour size, and improved survival. Now we need to see the effect on the immune system. Is the improvement also awakening the ‘good side’ of the immune system (T cells, natural killer cells) that helps to kill the tumour?” says Professor Jesus Gil, senior author and Head of the Senescence group at the LMS.
Zombie cells don’t grow, but they poison the tumor environment
Zombie cells act like bad neighbors. They don’t attack outright, but they stir up chaos—spewing signals, warping nearby cells, and crafting a tumor-friendly zone.
In tumors, they fan inflammation, shield cancer cells, and sometimes amp up aggression. They even lure immune cells that get hijacked to help the cancer instead of fighting it.
That’s why scientists have chased senolytics—drugs that zap these cells selectively. Past efforts targeted apoptosis (standard cell suicide). This study flips the script: exploiting ferroptosis vulnerability.
Human treatments are still distant, but the fit is coming into view
These compounds have only hit cells and mice so far. Way too soon for patient trials. Still, they shine in high-GPX4 tumors, where that shield lets zombie cells tough it out.
Down the line, docs might scan tumors for this Achilles’ heel. Chemo first to senescence-ify parts of it, then senolytics to finish the job.
It won’t replace chemo or immunotherapy—it’ll team up with them. The big hurdle? Nailing senescent cells without collateral damage to healthy tissue. That’ll make or break if this lab breakthrough hits clinics.
